Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...
EMA creates advice portal for some high-risk medical devices
The European Medicines Agency said the portal will enable consultations with medical device expert panels that can promote faster access to new technologies.
Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript
Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...
Business Wire2d
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...
CVM: Fiscal Year 2024 Results
CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) reports fiscal year 2024 financial and operational ...
Actuate Therapeutics sets annual meeting for May 22
Actuate Therapeutics , Inc., a biopharmaceutical company with a market capitalization of $172 million, announced today that it will hold its first Annual Meeting of Stockholders virtually on May 22, ...
Upgrading manufacturing quality standards for Indian pharma
This article is authored by Ranjit Barshikar, CEO, QbD International, CGMP Consulting, United Nations Adviser.
centerforbiosimilars6d
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...